Alcatel Lucent SA (ADR) (NYSE:ALU) ended the last trading day at $3.55. Company weekly volatility is calculated as 2.28% and price to cash ratio as 1.54. Alcatel Lucent SA (ADR) (NYSE:ALU) showed a weekly performance of 1.72%. China Mobile and Alcatel-Lucent SA (ADR) (NYSE:ALU) claimed on Monday to have conducted the industry’s first field test of a virtualised radio access network (vRAN) using network functions virtualisation (NFV) technology.
Synthetic Biologics Inc. (NYSEMKT:SYN) shares advanced 14.80% in last trading session and ended the day at $3.49. SYN return on assets is -242.70%. Synthetic Biologics Inc. (NYSEMKT:SYN) quarterly performance is 53.74%. Synthetic Biologics Inc. (NYSEMKT:SYN) on June 29, 2015, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). This is a placebo-controlled study to evaluate the ability of two dose strengths of SYN-010 to reduce the production of methane in breath methane-positive patients with IBS-C. Breath methane is strongly associated with constipation in IBS-C and higher methane levels are proportional to constipation severity.
On 13 July, Rofin-Sinar Technologies Inc. (NASDAQ:RSTI) shares advanced 0.79% and was closed at $26.82. RSTI EPS growth in last 5 year was 23.50%. Rofin-Sinar Technologies Inc. (NASDAQ:RSTI) year to date (YTD) performance is -6.78%. Rofin-Sinar Technologies, Inc. (NASDAQ:RSTI) is scheduled to report earnings for the current quarter on 06 August 2015.
Tyco International Ltd. (NYSE:TYC) ended the last trading day at $38.13. Company weekly volatility is calculated as 1.70% and price to cash ratio as 37.16. Tyco International Ltd. (NYSE:TYC) showed a weekly performance of -0.21%. Tyco Intl Ltd. (NYSE: TYC) on 8 July, announced the appointment ofJohan F. Pfeiffer as Executive Vice President, Rest of World Installation & Services. In this role, Mr. Pfeiffer will have responsibility for Tyco’s commercial fire and security and residential security businesses in all regions outside of North America, a segment with $3.9 billion in revenue in fiscal year 2014.
Pfizer Inc. (NYSE:PFE) shares advanced 1.34% in last trading session and ended the day at $34.82. PFE Gross Margin is 81.00% and its return on assets is 6.80%. Pfizer Inc. (NYSE:PFE) quarterly performance is 0.05%. Pfizer Inc. (NYSE:PFE) announced enrollment of the first patient in a phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery.